## Wolfgang Wadsak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9326320/publications.pdf

Version: 2024-02-01

257 papers 6,767 citations

57758 44 h-index 66 g-index

288 all docs

288 docs citations

times ranked

288

7903 citing authors

#	Article	IF	CITATIONS
1	EANM position on the in-house preparation of radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1095-1098.	6.4	12
2	Simultaneous radiomethylation of $[11C]$ harmine and $[11C]$ DASB and kinetic modeling approach for serotonergic brain imaging in the same individual. Scientific Reports, 2022, 12, 3283.	3.3	0
3	Design, Synthesis, and Biological Evaluation of 4,4'-Difluorobenzhydrol Carbamates as Selective M1 Antagonists. Pharmaceuticals, 2022, 15, 248.	3.8	4
4	Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends. Frontiers in Nuclear Medicine, 2022, 2, .	1.2	3
5	Status-Quo-Erhebung zur Zyklotron-Infrastruktur für die Nuklearmedizin und Radiopharmazie in Deutschland, Österreich und der Schweiz. Nuklearmedizin - NuclearMedicine, 2022, 61, .	0.7	0
6	Learning induces coordinated neuronal plasticity of metabolic demands and functional brain networks. Communications Biology, 2022, 5, 428.	4.4	9
7	Synthesis, Biological Evaluation, and Docking Studies of Antagonistic Hydroxylated Arecaidine Esters Targeting mAChRs. Molecules, 2022, 27, 3173.	3.8	4
8	Imaging Inflammation in Atherosclerosis with CXCR4-Directed [68Ga]PentixaFor PET/MRIâ€"Compared with [18F]FDG PET/MRI. Life, 2022, 12, 1039.	2.4	3
9	A Microdosing Study with <sup>99m</sup> Tc-PHC-102 for the SPECT/CT Imaging of Primary and Metastatic Lesions in Renal Cell Carcinoma Patients. Journal of Nuclear Medicine, 2021, 62, 360-365.	5.0	20
10	On the consensus nomenclature rules for radiopharmaceutical chemistry – Reconsideration of radiochemical conversion. Nuclear Medicine and Biology, 2021, 93, 19-21.	0.6	43
11	Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1795-1805.	6.4	72
12	Prediction of response and survival after standardized treatment with 7400ÂMBq 177Lu-PSMA-617 every 4Âweeks in patients with metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1650-1657.	6.4	21
13	Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivity–impulsivity symptoms in ADHD measured with PET. Molecular Psychiatry, 2021, 26, 1009-1018.	7.9	23
14	Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia. Neurolmage: Clinical, 2021, 32, 102813.	2.7	5
15	Functional dynamics of dopamine synthesis during monetary reward and punishment processing. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2973-2985.	4.3	17
16	Reliability of task-specific neuronal activation assessed with functional PET, ASL and BOLD imaging. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2986-2999.	4.3	18
17	Update on PET Tracer Development for Muscarinic Acetylcholine Receptors. Pharmaceuticals, 2021, 14, 530.	3.8	11
18	Impact of the COVID-19 pandemic on nuclear medicine departments in Europe. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3361-3364.	6.4	6

#	Article	IF	CITATIONS
19	High-dose testosterone treatment reduces monoamine oxidase A levels in the human brain: A preliminary report. Psychoneuroendocrinology, 2021, 133, 105381.	2.7	11
20	Discovery of melanin oncentrating hormone receptor 1 in brown adipose tissue. Annals of the New York Academy of Sciences, 2021, 1494, 70-86.	3.8	2
21	First-in-human brain PET imaging of the GluN2B-containing N-methyl-D-aspartate receptor with (R)-11C-Me-NB1. Journal of Nuclear Medicine, 2021, , jnumed.121.262427.	5.0	14
22	Unexpected scaffold rearrangement product of pirenzepine found in commercial samples. Scientific Reports, 2021, 11, 23397.	3.3	1
23	Brain glucose uptake during transcranial direct current stimulation measured with functional [18F]FDG-PET. Brain Imaging and Behavior, 2020, 14, 477-484.	2.1	5
24	PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 51-60.	6.4	98
25	Response assessment using [ <sup>68</sup> Ga]Gaâ€PSMA ligand PET in patients undergoing systemic therapy for metastatic castrationâ€resistant prostate cancer. Prostate, 2020, 80, 74-82.	2.3	49
26	Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 713-720.	6.4	46
27	Enhanced arecoline derivatives as muscarinic acetylcholine receptor M1 ligands for potential application as PET radiotracers. European Journal of Medicinal Chemistry, 2020, 204, 112623.	5.5	8
28	Synthesis, Biological, and Computational Evaluation of Antagonistic, Chiral Hydrobenzoin Esters of Arecaidine Targeting mAChR M1. Pharmaceuticals, 2020, 13, 437.	3.8	6
29	The relationship between cholecystokinin secretion and pancreatic [11C]methionine uptake in patients after partial pancreaticoduodenectomy. Annals of Nuclear Medicine, 2020, 34, 691-695.	2.2	0
30	Association of dopamine D2/3 receptor binding potential measured using PET and $[11C]$ -(+)-PHNO with post-mortem DRD2/3 gene expression in the human brain. NeuroImage, 2020, 223, 117270.	4.2	11
31	Training the next generation of radiopharmaceutical scientists. Nuclear Medicine and Biology, 2020, 88-89, 10-13.	0.6	7
32	Topologically Guided Prioritization of Candidate Gene Transcripts Coexpressed with the 5-HT1A Receptor by Combining In Vivo PET and Allen Human Brain Atlas Data. Cerebral Cortex, 2020, 30, 3771-3780.	2.9	10
33	Utility of Absolute Quantification in Non-lesional Extratemporal Lobe Epilepsy Using FDG PET/MR Imaging. Frontiers in Neurology, 2020, 11, 54.	2.4	21
34	On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study. Translational Psychiatry, 2020, 10, 2.	4.8	25
35	Machine learning classification of ADHD and HC by multimodal serotonergic data. Translational Psychiatry, 2020, 10, 104.	4.8	39
36	<i> <scp>STAT</scp> 3 </i> â€dependent analysis reveals <i> <scp>PDK</scp> 4 </i> as independent predictor of recurrence in prostate cancer. Molecular Systems Biology, 2020, 16, e9247.	7.2	38

#	Article	IF	Citations
37	Reconfiguration of functional brain networks and metabolic cost converge during task performance. ELife, 2020, 9, .	6.0	49
38	SNAPshots of the MCHR1: a Comparison Between the PET-Tracers [18F]FE@SNAP and [11C]SNAP-7941. Molecular Imaging and Biology, 2019, 21, 257-268.	2.6	5
39	Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [ <sup>68</sup> Ga]Ga-Pentixafor-PET/MRI. Theranostics, 2019, 9, 3653-3658.	10.0	42
40	Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR. Frontiers in Molecular Neuroscience, 2019, 12, 172.	2.9	6
41	Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2169-2177.	6.4	30
42	In vitro Radiopharmaceutical Evidence for MCHR1 Binding Sites in Murine Brown Adipocytes. Frontiers in Endocrinology, 2019, 10, 324.	3.5	6
43	Synthesis and in vitro evaluation of new translocator protein ligands designed for positron emission tomography. Future Medicinal Chemistry, 2019, 11, 539-550.	2.3	3
44	Toward the Optimization of (+)-[11C]PHNO Synthesis: Time Reduction and Process Validation. Contrast Media and Molecular Imaging, 2019, 2019, 1-13.	0.8	1
45	Sex-differences in [68Ga]Ga-DOTANOC biodistribution. Nuclear Medicine and Biology, 2019, 76-77, 15-20.	0.6	4
46	PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2â <sup>^</sup> Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT. Molecular Imaging and Biology, 2019, 21, 991-1002.	2.6	8
47	Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression. Translational Psychiatry, 2019, 9, 5.	4.8	7
48	Binding Affinity of Some Endogenous and Synthetic TSPO Ligands Regarding the rs6971 Polymorphism. International Journal of Molecular Sciences, 2019, 20, 563.	4.1	13
49	Multimodal [18F]FDG PET/CT Is a Direct Readout for Inflammatory Bone Repair: A Longitudinal Study in TNFα Transgenic Mice. Journal of Bone and Mineral Research, 2019, 34, 1632-1645.	2.8	8
50	Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging. European Neuropsychopharmacology, 2019, 29, 711-719.	0.7	11
51	(R)-[18F]NEBIFQUINIDE: A promising new PET tracer for TSPO imaging. European Journal of Medicinal Chemistry, 2019, 176, 410-418.	5.5	14
52	Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [ $\sup 11 < \sup C$ ]SNAP-7941. Journal of Visualized Experiments, 2019, , .	0.3	2
53	Characterization of pharmacological response to selective serotonin reuptake inhibitors using clustering of resting-state hybrid PET/MR data. European Neuropsychopharmacology, 2019, 29, S603-S604.	0.7	0
54	[68Ga]Pentixafor PET/MR imaging of chemokine receptor 4 expression in the human carotid artery. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1616-1625.	6.4	49

#	Article	IF	CITATIONS
55	FDG ―PET / MRI imaging for the management of alveolar echinococcosis: initial clinical experience at a reference centre in Austria. Tropical Medicine and International Health, 2019, 24, 663-670.	2.3	15
56	Characterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using <sup>18</sup> F-FDG-PET/CT and <sup>18</sup> F-NaF-PET/CT. Anticancer Research, 2019, 39, 1943-1952.	1.1	3
57	The Radiopharmaceutical Chemistry of Carbon-11: Tracers and Applications., 2019,, 221-236.		1
58	Sequential [ $\langle \sup 18 \langle \sup F]$ FDG-[ $\langle \sup 18 \langle \sup F]$ FMISO PET and Multiparametric MRI at 3T for Insights into Breast Cancer Heterogeneity and Correlation with Patient Outcomes: First Clinical Experience. Contrast Media and Molecular Imaging, 2019, 2019, 1-9.	0.8	9
59	Attenuation Correction Approaches for Serotonin Transporter Quantification With PET/MRI. Frontiers in Physiology, 2019, 10, 1422.	2.8	5
60	Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1063-1072.	6.4	100
61	The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. Brain Stimulation, 2019, 12, 714-723.	1.6	24
62	Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate <sup>11</sup> C-Metoclopramide Assessed with PET Imaging in Humans. Journal of Nuclear Medicine, 2019, 60, 985-991.	5.0	38
63	Optimization of the Automated Synthesis of [11C]mHEDâ€"Administered and Apparent Molar Activities. Pharmaceuticals, 2019, 12, 12.	3.8	1
64	Parcellation of the Human Cerebral Cortex Based on Molecular Targets in the Serotonin System Quantified by Positron Emission Tomography In vivo. Cerebral Cortex, 2019, 29, 372-382.	2.9	12
65	A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood–Brain Barrier. Journal of Nuclear Medicine, 2019, 60, 486-491.	5.0	25
66	Pitfalls and solutions of the fully-automated radiosynthesis of [11C]metoclopramide. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 31.	3.9	7
67	Explorative analysis of retrospective data of patients with esophageal cancer at the Department of Nuclear Medicine at the Medical University of Vienna: Predicting 30-month survival and progress-free survival using Supervised Machine Learning. Nuklearmedizin - NuclearMedicine, 2019, 58, .	0.7	O
68	Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity. Brain Structure and Function, 2018, 223, 1369-1378.	2.3	34
69	[ <sup>18</sup> F]FEPPA: Improved Automated Radiosynthesis, Binding Affinity, and Preliminary in Vitro Evaluation in Colorectal Cancer. ACS Medicinal Chemistry Letters, 2018, 9, 177-181.	2.8	15
70	[18F]FDG-PET/CT and MRI for initial pelvic lymph node staging in patients with cervical carcinoma: The potential usefulness of [18F]FDG-PET/MRI. Oncology Letters, 2018, 15, 3951-3956.	1.8	4
71	A new method measuring the interaction of radiotracers with the human P-glycoprotein (P-gp) transporter. Nuclear Medicine and Biology, 2018, 60, 29-36.	0.6	5
72	[11C]acetate PET as a tool for diagnosis of liver steatosis. Abdominal Radiology, 2018, 43, 2963-2969.	2.1	3

#	Article	IF	Citations
73	Probing the association between serotonin-1A autoreceptor binding and amygdala reactivity in healthy volunteers. Neurolmage, 2018, 171, 1-5.	4.2	6
74	Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging. NeuroImage, 2018, 176, 259-267.	4.2	87
75	Microfluidic <sup>68</sup> Ga-labeling: a proof of principle study. Dalton Transactions, 2018, 47, 5997-6004.	3.3	9
76	Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET. Molecular Imaging and Biology, 2018, 20, 160-169.	2.6	16
77	Visual and semiquantitative $11\text{C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-na$\tilde{A}^{-}$ve gliomas. Neuro-Oncology, 2018, 20, 411-419.$	1.2	22
78	$68$ Ga-PSMA $11$ ligand PET imaging in patients with biochemical recurrence after radical prostatectomy $\hat{a} \in \text{``diagnostic}$ performance and impact on therapeutic decision-making. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 235-242.	6.4	89
79	[68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 558-566.	6.4	60
80	Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography. Clinical Pharmacology and Therapeutics, 2018, 104, 139-147.	4.7	43
81	Glioma Survival Prediction with Combined Analysis of In Vivo <sup>11</sup> C-MET PET Features, Ex Vivo Features, and Patient Features by Supervised Machine Learning. Journal of Nuclear Medicine, 2018, 59, 892-899.	5.0	94
82	Expanding LogP: Present possibilities. Nuclear Medicine and Biology, 2018, 58, 20-32.	0.6	17
83	Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [ <sup>18</sup> F]FDGâ€PET imaging. Is it of value in asymptomatic patients?. Pediatric Blood and Cancer, 2018, 65, e26733.	1.5	35
84	Development and evaluation of a rapid analysis for HEPES determination in 68Ga-radiotracers. EJNMMI Research, 2018, 8, 95.	2.5	8
85	Comparison of fully-automated radiosyntheses of [11C]erlotinib for preclinical and clinical use starting from in target produced [11C]CO2 or [11C]CH4. EJNMMI Radiopharmacy and Chemistry, 2018, 3, 8.	3.9	10
86	Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy. Translational Psychiatry, 2018, 8, 198.	4.8	22
87	Molar activity – The keystone in 11C-radiochemistry: An explorative study using the gas phase method. Nuclear Medicine and Biology, 2018, 67, 21-26.	0.6	4
88	L-[S-methyl-11C]methionine $\hat{a} \in \text{``An example of radiosynthetic optimization. Applied Radiation and Isotopes, 2018, 141, 107-111.}$	1.5	3
89	Effect of Rifampicin on the Distribution of $[\langle sup \rangle 11 \langle sup \rangle C]$ Erlotinib to the Liver, a Translational PET Study in Humans and in Mice. Molecular Pharmaceutics, 2018, 15, 4589-4598.	4.6	17
90	Reduced task durations in functional PET imaging with [18F]FDG approaching that of functional MRI. NeuroImage, 2018, 181, 323-330.	4.2	59

#	Article	IF	Citations
91	Preclinical <i>In Vitro</i> and <i>In Vivo</i> Evaluation of [ <sup>18</sup> F]FE@SUPPY for Cancer PET Imaging: Limitations of a Xenograft Model for Colorectal Cancer. Contrast Media and Molecular Imaging, 2018, 2018, 1-9.	0.8	5
92	An Overview of PET Radiochemistry, Part 1: The Covalent Labels <sup>18</sup> F, <sup>11</sup> C, and <sup>13</sup> N. Journal of Nuclear Medicine, 2018, 59, 1350-1354.	5.0	26
93	PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. Clinical Cancer Research, 2018, 24, 6300-6307.	7.0	112
94	Speed matters to raise molar radioactivity: Fast HPLC shortens the quality control of C-11 PET-tracers. Nuclear Medicine and Biology, 2018, 57, 28-33.	0.6	12
95	Clinical Value of 18F-FDOPA PET/CT With Contrast Enhancement and Without Carbidopa Premedication in Patients with Insulinoma. Anticancer Research, 2018, 38, 353-358.	1.1	12
96	**-Postprandial pancreatic [11C]methionine uptake after pancreaticoduodenectomy mirrors basal beta cell function and insulin release. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 509-516.	6.4	3
97	Simple and rapid quantification of serotonin transporter binding using [11C]DASB bolus plus constant infusion. Neurolmage, 2017, 149, 23-32.	4.2	19
98	New approaches for the reliable in vitro assessment of binding affinity based on high-resolution real-time data acquisition of radioligand-receptor binding kinetics. EJNMMI Research, 2017, 7, 22.	2.5	24
99	Association Between Osteogenesis and Inflammation During the Progression of Calcified Plaque Evaluated by <sup>18</sup> F-Fluoride and <sup>18</sup> F-FDG. Journal of Nuclear Medicine, 2017, 58, 968-974.	5.0	40
100	Effect of Pâ€glycoprotein inhibition at the blood–brain barrier on brain distribution of ( <i>R</i> )â€{ <sup>11</sup> C]verapamil in elderly <i>vs.</i> young subjects. British Journal of Clinical Pharmacology, 2017, 83, 1991-1999.	2.4	28
101	Association of Protein Distribution and Gene Expression Revealed by PET and Post-Mortem Quantification in the Serotonergic System of the Human Brain. Cerebral Cortex, 2017, 27, 117-130.	2.9	30
102	The influence of the rs6295 gene polymorphism on serotonin-1A receptor distribution investigated with PET in patients with major depression applying machine learning. Translational Psychiatry, 2017, 7, e1150-e1150.	4.8	22
103	Log P , a yesterday's value?. Nuclear Medicine and Biology, 2017, 50, 1-10.	0.6	62
104	In vivo evaluation of radiotracers targeting the melanin-concentrating hormone receptor 1: [11C]SNAP-7941 and [18F]FE@SNAP reveal specific uptake in the ventricular system. Scientific Reports, 2017, 7, 8054.	3.3	6
105	In vivo magnetic resonance imaging of pancreatic tumors using iron oxide nanoworms targeted with PTR86 peptide. Colloids and Surfaces B: Biointerfaces, 2017, 158, 423-430.	5.0	11
106	Impact of hybrid PET/MR technology on multiparametric imaging and treatment response assessment of cervix cancer. Radiotherapy and Oncology, 2017, 125, 420-425.	0.6	25
107	The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1732-1741.	6.4	20
108	Assessment of P-Glycoprotein Transport Activity at the Human Blood–Retina Barrier with ( <i>R</i> )â€≺sup>11C-Verapamil PET. Journal of Nuclear Medicine, 2017, 58, 678-681.	5.0	23

#	Article	IF	Citations
109	Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET. Human Brain Mapping, 2017, 38, 792-802.	3.6	21
110	Monoamine oxidase A distribution volume as a correlate for electroconvulsive therapy – preliminary results. European Neuropsychopharmacology, 2017, 27, S708-S709.	0.7	1
111	Influence of serotonergic gene variants on serotonin transporter binding in ADHD. European Neuropsychopharmacology, 2017, 27, S707.	0.7	0
112	Reproducibility of Quantitative Brain Imaging Using a PET-Only and a Combined PET/MR System. Frontiers in Neuroscience, 2017, 11, 396.	2.8	8
113	Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression. Frontiers in Human Neuroscience, 2017, 11, 48.	2.0	50
114	Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer. PLoS ONE, 2017, 12, e0180790.	2.5	7
115	Development of a radiolabeled caninized anti-EGFR antibody for comparative oncology trials. Oncotarget, 2017, 8, 83128-83141.	1.8	7
116	Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study. PLoS ONE, 2016, 11, e0155333.	2.5	45
117	PM478. Imaging the effects of d-amphetamine in the human brain for modelling dopaminergic alterations in schizophrenia. International Journal of Neuropsychopharmacology, 2016, 19, 74-74.	2.1	1
118	PS168. Hybrid PET/MR imaging of serotonin transporter occupancy and brain activation to elucidate the mechanism of action of selective serotonin reuptake inhibitors. International Journal of Neuropsychopharmacology, 2016, 19, 60-61.	2.1	0
119	Quantification of Task-Specific Glucose Metabolism with Constant Infusion of <sup> 18 &lt; /sup &gt; F-FDG. Journal of Nuclear Medicine, 2016, 57, 1933-1940.</sup>	5.0	64
120	Attenuation of habenula–default mode network connectivity by selective serotonin reuptake inhibitors, a pharmacological hybrid PET/MR study. European Neuropsychopharmacology, 2016, 26, S317.	0.7	1
121	Insights into Intrinsic Brain Networks based on Graph Theory and PET in right- compared to left-sided Temporal Lobe Epilepsy. Scientific Reports, 2016, 6, 28513.	3.3	24
122	Neurochemical and behavioral sensitization to d-amphetamine in healthy subjects measured with [ <sup>11</sup> C]-(+)-PHNO-PET. European Psychiatry, 2016, 33, S105-S106.	0.2	0
123	32nd International Austrian Winter Symposium. EJNMMI Research, 2016, 6, 32.	2.5	0
124	Presurgical evaluation of pediatric epilepsy patients prior to hemispherotomy: the prognostic value of 18F-FDG PET. Journal of Neurosurgery: Pediatrics, 2016, 18, 683-688.	1.3	9
125	Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood–Brain Barrier. Clinical Pharmacology and Therapeutics, 2016, 100, 131-141.	4.7	50
126	Whole-Body Distribution and Radiation Dosimetry of <sup>11</sup> C-Elacridar and <sup>11</sup> C-Tariquidar in Humans. Journal of Nuclear Medicine, 2016, 57, 1265-1268.	5.0	11

#	Article	IF	CITATIONS
127	Quantitative Assessment of Breast Parenchymal Uptake on <sup>18</sup> F-FDG PET/CT: Correlation with Age, Background Parenchymal Enhancement, and Amount of Fibroglandular Tissue on MRI. Journal of Nuclear Medicine, 2016, 57, 1518-1522.	5.0	19
128	[18F]FMeNER-D2: A systematic in vitro analysis of radio-metabolism. Nuclear Medicine and Biology, 2016, 43, 490-495.	0.6	6
129	[18F]FE@SNAPâ€"a specific PET tracer for melanin-concentrating hormone receptor 1 imaging?. EJNMMI Research, 2016, 6, 31.	2.5	8
130	Effects of norepinephrine transporter gene variants on <scp>NET</scp> binding in <scp>ADHD</scp> and healthy controls investigated by <scp>PET</scp> . Human Brain Mapping, 2016, 37, 884-895.	3.6	37
131	Development of a Novel Nonpeptidic <sup>18</sup> F-Labeled Radiotracer for in Vivo Imaging of Oxytocin Receptors with Positron Emission Tomography. Journal of Medicinal Chemistry, 2016, 59, 1800-1817.	6.4	17
132	Quantitative assessment of atherosclerotic plaques on 18F-FDG PET/MRI: comparison with a PET/CT hybrid system. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1503-1512.	6.4	38
133	P.1.i.047 Interregional changes in serotonin transporter availability upon treatment with selective serotonin reuptake inhibitors. European Neuropsychopharmacology, 2015, 25, S327-S328.	0.7	0
134	Radiosynthesis and first preclinical evaluation of the novel norepinephrine transporter pet-ligand [11C]ME@HAPTHI. EJNMMI Research, 2015, 5, 113.	2.5	11
135	Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [ <sup>11</sup> C]acetate PET as a prognostic marker. Prostate, 2015, 75, 1760-1767.	2.3	28
136	2-Fluoro-N-methyl-N-({(3S,4S)-4-[2-(trifluoromethyl)phenoxy]-3,4-dihydro-1H-isochromen-3-yl}methyl)ethanamine MolBank, 2015, 2015, M858.	 0.5	0
137	1-(3-Amino-1-phenylpropyl)-3-(2-fluorophenyl)-1,3-dihydro-2H-benzimidazol-2-one. MolBank, 2015, 2015, M867.	0.5	0
138	Synthesis and in Silico Evaluation of Novel Compounds for PET-Based Investigations of the Norepinephrine Transporter. Molecules, 2015, 20, 1712-1730.	3.8	6
139	2-Fluoro-N-methyl-N-{[(3S*,4S*)-4-(2-methylphenoxy)-3,4-dihydro-1H-isochromen-3-yl]methyl}ethanamine. MolBank, 2015, 2015, M862.	0.5	O
140	Parameter evaluation and fully-automated radiosynthesis of [ 11 C]harmine for imaging of MAO-A for clinical trials. Applied Radiation and Isotopes, 2015, 97, 182-187.	1.5	16
141	[18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 741-749.	6.4	5
142	High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People. Biological Psychiatry, 2015, 78, 525-533.	1.3	75
143	Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding. Neurolmage, 2015, 111, 505-512.	4.2	12
144	Approaching Complete Inhibition of P-Glycoprotein at the Human Blood–Brain Barrier: An ( <i>R</i> )-[ <sup>11</sup> C]Verapamil PET Study. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 743-746.	4.3	74

#	Article	IF	Citations
145	Hide and seek: a comparative autoradiographic in vitro investigation of the adenosine A3 receptor. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 928-939.	6.4	17
146	Effects of Silexan on the Serotonin-1A Receptor and Microstructure of the Human Brain: A Randomized, Placebo-Controlled, Double-Blind, Cross-Over Study with Molecular and Structural Neuroimaging. International Journal of Neuropsychopharmacology, 2015, 18, pyu063-pyu063.	2.1	49
147	P.1.i.037 Effects of norepinephrine transporter gene variants on protein binding in patients with ADHD using PET. European Neuropsychopharmacology, 2015, 25, S321-S322.	0.7	O
148	Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence. Anticancer Research, 2015, 35, 6787-91.	1.1	15
149	A One-Step Microwave-Assisted Synthetic Method for an O/S-Chemoselective Route to Derivatives of the First Adenosine A3 PET Radiotracer. Molecules, 2014, 19, 4076-4082.	3.8	0
150	Attenuated serotonin transporter association between dorsal raphe and ventral striatum in major depression. Human Brain Mapping, 2014, 35, 3857-3866.	3.6	50
151	The Norepinephrine Transporter in Attention-Deficit/Hyperactivity Disorder Investigated With Positron Emission Tomography. JAMA Psychiatry, 2014, 71, 1340.	11.0	44
152	Imaging Biomarkers or Biomarker Imaging?. Pharmaceuticals, 2014, 7, 765-778.	3.8	13
153	Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [carbonyl-11C]WAY-100635. Psychoneuroendocrinology, 2014, 45, 1-10.	2.7	23
154	Relation of progesterone and DHEAS serum levels to 5-HT1A receptor binding potential in pre- and postmenopausal women. Psychoneuroendocrinology, 2014, 46, 52-63.	2.7	19
155	Impact of COMT genotype on serotonin-1A receptor binding investigated with PET. Brain Structure and Function, 2014, 219, 2017-2028.	2.3	13
156	Cerebral serotonin transporter asymmetry in females, males and male-to-female transsexuals measured by PET in vivo. Brain Structure and Function, 2014, 219, 171-183.	2.3	28
157	In vivo P-glycoprotein function before and after epilepsy surgery. Neurology, 2014, 83, 1326-1331.	1.1	37
158	Development of potential selective and reversible pyrazoline based MAO-B inhibitors as MAO-B PET tracer precursors and reference substances for the early detection of Alzheimer's disease. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4490-4495.	2.2	9
159	Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET. Neurolmage, 2014, 88, 252-262.	4.2	54
160	Comparative autoradiographic in vitro investigation of melanin concentrating hormone receptor 1 ligands in the central nervous system. European Journal of Pharmacology, $2014, 735, 177-183$ .	3 <b>.</b> 5	10
161	Exploring the Impact of BDNF Val66Met Genotype on Serotonin Transporter and Serotonin-1A Receptor Binding. PLoS ONE, 2014, 9, e106810.	2.5	11
162	Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET. Anticancer Research, 2014, 34, 6647-54.	1.1	12

#	Article	IF	CITATIONS
163	Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. European Radiology, 2013, 23, 1978-1985.	4.5	41
164	Preclinical in vitro & amp; in vivo evaluation of [11C]SNAP-7941 – the first PET tracer for the melanin concentrating hormone receptor 1. Nuclear Medicine and Biology, 2013, 40, 919-925.	0.6	20
165	P.2.b.044 Serotonin transporter association between dorsal raphe and ventral striatum is diminished in major depression. European Neuropsychopharmacology, 2013, 23, S345.	0.7	0
166	Synthesis, radiosynthesis and first in vitro evaluation of novel PET-tracers for the dopamine transporter: [11C]IPCIT and [18F]FE@IPCIT. Bioorganic and Medicinal Chemistry, 2013, 21, 7562-7569.	3.0	8
167	Impact of electroconvulsive therapy on 5-HT1A receptor binding in major depression. Molecular Psychiatry, 2013, 18, 1-1.	7.9	10
168	Reliable set-up for in-loop 11C-carboxylations using Grignard reactions for the preparation of [carbonyl-11C]WAY-100635 and [11C]-(+)-PHNO. Applied Radiation and Isotopes, 2013, 82, 75-80.	1.5	20
169	[18F]FMeNER-D2: Reliable fully-automated synthesis for visualization of the norepinephrine transporter. Nuclear Medicine and Biology, 2013, 40, 1049-1054.	0.6	17
170	Application of image-derived and venous input functions in major depression using [carbonyl-11C]WAY-100635. Nuclear Medicine and Biology, 2013, 40, 371-377.	0.6	62
171	Development and automation of a novel NET-PET tracer: [11C]Me@APPI. Nuclear Medicine and Biology, 2013, 40, 295-303.	0.6	11
172	Interaction of <sup>11</sup> C-Tariquidar and <sup>11</sup> C-Elacridar with P-Glycoprotein and Breast Cancer Resistance Protein at the Human Blood–Brain Barrier. Journal of Nuclear Medicine, 2013, 54, 1181-1187.	5.0	45
173	Preparation and First Preclinical Evaluation of [18F]FE@SNAP: A Potential PET Tracer for the Melanin Concentrating Hormone Receptor 1 (MCHR1). Scientia Pharmaceutica, 2013, 81, 625-639.	2.0	14
174	Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. Molecular Psychiatry, 2013, 18, 93-100.	7.9	98
175	Syntheses of Precursors and Reference Compounds of the Melanin-Concentrating Hormone Receptor 1 (MCHR1) Tracers [11C]SNAP-7941 and [18F]FE@SNAP for Positron Emission Tomography. Molecules, 2013, 18, 12119-12143.	3.8	5
176	Differential modulation of the default mode network via serotonin-1A receptors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2619-2624.	7.1	109
177	Quantification of the radio-metabolites of the serotonin-1A receptor radioligand [carbonyl-11C]WAY-100635 in human plasma: An HPLC-assay which enables measurement of two patients in parallel. Applied Radiation and Isotopes, 2012, 70, 2730-2736.	1.5	3
178	P.4.002 Serotonin transporter ratio between raphe nuclei and projection areas predicts SSRI treatment response in major depression. European Neuropsychopharmacology, 2012, 22, S85.	0.7	0
179	Light-dependent alteration of serotonin-1A receptor binding in cortical and subcortical limbic regions in the human brain. World Journal of Biological Psychiatry, 2012, 13, 413-422.	2.6	57
180	Single-step radiofluorination of peptides using continuous flow microreactor. Organic and Biomolecular Chemistry, 2012, 10, 3871.	2.8	17

#	Article	IF	CITATIONS
181	Radiosynthesis of [11C]SNAP-7941â€"the first PET-tracer for the melanin concentrating hormone receptor 1 (MCHR1). Applied Radiation and Isotopes, 2012, 70, 2287-2294.	1.5	15
182	Optimization of [11C]DASB-synthesis: Vessel-based and flow-through microreactor methods. Applied Radiation and Isotopes, 2012, 70, 2615-2620.	1.5	14
183	[18F]FE@SNAPâ€"A new PET tracer for the melanin concentrating hormone receptor 1 (MCHR1): Microfluidic and vessel-based approaches. Bioorganic and Medicinal Chemistry, 2012, 20, 5936-5940.	3.0	28
184	Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl-11C]WAY-100635 independent of arterial sampling. NeuroImage, 2012, 62, 199-206.	4.2	19
185	Normative database of the serotonergic system in healthy subjects using multi-tracer PET. NeuroImage, 2012, 63, 447-459.	4.2	126
186	Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. NeuroImage, 2012, 63, 874-881.	4.2	124
187	Serotonin-1A receptor binding is positively associated with gray matter volume â€" A multimodal neuroimaging study combining PET and structural MRI. NeuroImage, 2012, 63, 1091-1098.	4.2	27
188	Radiolabeling of [18F]altanserin â€" a microfluidic approach. Nuclear Medicine and Biology, 2012, 39, 1087-1092.	0.6	25
189	Pgp-Mediated Interaction Between (R)-[11C]Verapamil and Tariquidar at the Human Blood–Brain Barrier: A Comparison With Rat Data. Clinical Pharmacology and Therapeutics, 2012, 91, 227-233.	4.7	108
190	FC10-05 - Attenuated serotonin transporter association between midbrain and nucleus accumbens in major depression. European Psychiatry, 2011, 26, 1868-1868.	0.2	0
191	Multimodal imaging of an astrocytoma affecting the amygdalar region. European Psychiatry, 2011, 26, 924-924.	0.2	0
192	Prediction of steady-state occupancy of the serotonin transporter based on single-dose occupancy: A [ <sup>11</sup> C]DASB pet study. European Psychiatry, 2011, 26, 929-929.	0.2	1
193	Cortisol plasma levels are associated with serotonin - 1A receptor binding in postmenopausal women. European Psychiatry, 2011, 26, 933-933.	0.2	0
194	The stability of methyl-, ethyl- and fluoroethylesters against carboxylesterases in vitro: there is no difference. Nuclear Medicine and Biology, 2011, 38, 13-17.	0.6	6
195	Microfluidic preparation of [18F]FE@SUPPY and [18F]FE@SUPPY:2 — comparison with conventional radiosyntheses. Nuclear Medicine and Biology, 2011, 38, 427-434.	0.6	25
196	Optimization of the radiosynthesis of the Alzheimer tracer 2-(4-N-[11C]methylaminophenyl)-6-hydroxybenzothiazole ([11C]PIB). Applied Radiation and Isotopes, 2011, 69, 1212-1217.	1.5	26
197	Progesterone Level Predicts Serotonin-1A Receptor Binding in the Male Human Brain. Neuroendocrinology, 2011, 94, 84-88.	2.5	18
198	Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. International Journal of Neuropsychopharmacology, 2010, 13, 1129-1143.	2.1	54

#	Article	IF	CITATIONS
199	"Label and go―– A fast and easy radiolabelling method for pellets. Applied Radiation and Isotopes, 2010, 68, 399-403.	1.5	0
200	Escitalopram Enhances the Association of Serotonin-1A Autoreceptors to Heteroreceptors in Anxiety Disorders. Journal of Neuroscience, 2010, 30, 14482-14489.	3.6	52
201	Segmentation of [11C]DASB and [carbonyl-11C]WAY-100635 PET brain images using linear discriminant analysis. Neurolmage, 2010, 52, S155-S156.	4.2	1
202	Hypothalamic serotonin-1A receptor binding measured by PET predicts the plasma level of dehydroepiandrosterone sulfate in healthy women. Neuroscience Letters, 2010, 476, 161-165.	2.1	15
203	Basics and principles of radiopharmaceuticals for PET/CT. European Journal of Radiology, 2010, 73, 461-469.	2.6	104
204	[18F]FE@SUPPY and [18F]FE@SUPPY:2 â€" metabolic considerations. Nuclear Medicine and Biology, 2010, 37, 421-426.	0.6	15
205	Central serotonin 1A receptor binding in temporal lobe epilepsy: A [carbonyl-11C]WAY-100635 PET study. Epilepsy and Behavior, 2010, 19, 467-473.	1.7	37
206	Aggression is related to frontal serotoninâ€1A receptor distribution as revealed by PET in healthy subjects. Human Brain Mapping, 2009, 30, 2558-2570.	3.6	84
207	Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders. Molecular Psychiatry, 2009, 14, 1040-1050.	7.9	87
208	Simple and rapid preparation of $[11C]$ DASB with high quality and reliability for routine applications. Applied Radiation and Isotopes, 2009, 67, 1654-1660.	1.5	27
209	Lateralization of the serotonin-1A receptor distribution in language areas revealed by PET. NeuroImage, 2009, 45, 598-605.	4.2	72
210	Automatisation and First Evaluation of [18F]FE@SUPPY:2, an Alternative PET-Tracer for the Adenosine A3 Receptor: A Comparison with [18F]FE@SUPPY. The Open Nuclear Medicine Journal, 2009, 1, 15-23.	0.2	8
211	Adrenal Carcinoma – Radionuclide Imaging. , 2009, , 29-42.		0
212	The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-11C]WAY-100635. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 2159-2168.	6.4	59
213	Preparation and first evaluation of [18F]FE@SUPPY: a new PET tracer for the adenosine A3 receptor. Nuclear Medicine and Biology, 2008, 35, 61-66.	0.6	28
214	Metabolism and autoradiographic evaluation of [18F]FE@CIT: a Comparison with [123I] $\hat{l}^2$ -CIT and [123I]FP-CIT. Nuclear Medicine and Biology, 2008, 35, 475-479.	0.6	5
215	Preparation and pre-vivo evaluation of no-carrier-added, carrier-added and cross-complexed [68Ga]-EDTMP formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 406-412.	4.3	27
216	S.07.04 Progesterone and estradiol plasma levels modulate serotonin-1A binding in the human brain. European Neuropsychopharmacology, 2008, 18, S168.	0.7	0

#	Article	IF	CITATIONS
217	Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET. NeuroImage, 2008, 41, 204-211.	4.2	32
218	Synthesis of in vivo Metabolites of the New Adenosine A3 Receptor PET-Radiotracer [18F]FE@SUPPY. Heterocycles, 2008, 75, 339.	0.7	8
219	Radiosynthesis of the adenosine A3 receptor ligand 5-(2-[18F]fluoroethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)- 6-phenylpyridine-5-carboxylate ([18F]FE@SUPPY). Radiochimica Acta, 2008, 96, .	1.2	7
220	Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Blood–Brain Barrier Studied with ( <i>R</i> )- <sup>11</sup> C-Verapamil and PET. Journal of Nuclear Medicine, 2008, 49, 1328-1335.	5.0	104
221	Simple and fully automated preparation of [carbonyl-11C]WAY-100635. Radiochimica Acta, 2007, 95, .	1.2	28
222	Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP. Nuclear Medicine and Biology, 2007, 34, 391-397.	0.6	37
223	Evaluation of novel tropane analogues. Nuclear Medicine and Biology, 2007, 34, 591-592.	0.6	0
224	18F fluoroethylations: different strategies for the rapid translation of 11C-methylated radiotracers. Nuclear Medicine and Biology, 2007, 34, 1019-1028.	0.6	20
225	Preparation and radiosynthesis of [18F]FE@CFN (2-[18F]fluoroethyl) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 receptor imaging agent. Radiochimica Acta, 2007, 95, .	50 427 Td 1.2	(4-[N-(1-ox(
226	Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder. Biological Psychiatry, 2007, 61, 1081-1089.	1.3	276
227	The presence of MOMAâ€2 < sup>+ macrophages in the outer B cell zone and protection of the splenic microâ€architecture from LPSâ€induced destruction depend on secreted IgM. European Journal of Immunology, 2007, 37, 2825-2833.	2.9	6
228	In vitro evaluation of no carrier added, carrier added and cross-complexed [90Y]-EDTMP provides evidence for a novel "foreign carrier theory― Nuclear Medicine and Biology, 2006, 33, 95-99.	0.6	9
229	NCA nucleophilic radiofluorination on substituted benzaldehydes for the preparation of [18F]fluorinated aromatic amino acids. Applied Radiation and Isotopes, 2006, 64, 355-359.	1.5	5
230	Uptake of bone-seekers is solely associated with mineralisation! A study with 99mTc-MDP, 153Sm-EDTMP and 18F-fluoride on osteoblasts. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 491-494.	6.4	74
231	[18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 669-672.	6.4	33
232	Imaging of adrenocortical metastases with $[11C]$ metomidate. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 974-974.	6.4	11
233	[18F]FETO: metabolic considerations. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 928-931.	6.4	19
234	New aspects on the preparation of [11C]Methionineâ€"a simple and fast online approach without preparative HPLC. Applied Radiation and Isotopes, 2005, 62, 441-445.	1.5	38

#	Article	IF	CITATIONS
235	Cold pressure testing 99 Tc MIBI-SPECT useful detecting abnormal coronary vasoreactivity in asymptomatic population with moderate risk of cardiovascular events. PARADIGMA multicenter study. Journal of Nuclear Cardiology, 2005, 12, S41-S41.	2.1	O
236	Influence of functional haplotypes in the drug transporter gene on central nervous system drug distribution in humans. Clinical Pharmacology and Therapeutics, 2005, 78, 182-190.	4.7	64
237	In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 143-150.	6.4	77
238	Synthesis and biodistribution of [18F]FE@CIT, a new potential tracer for the dopamine transporter. Synapse, 2005, 55, 73-79.	1,2	16
239	Binding studies of [18F]-fluoride and polyphosphonates radiolabelled with [99mTc], [111In], [153Sm] and [188Re] on bone compartments: Verification of the pre vivo model?. Bone, 2005, 37, 404-412.	2.9	20
240	[ 18 F]Ciprofloxacin, a New Positron Emission Tomography Tracer for Noninvasive Assessment of the Tissue Distribution and Pharmacokinetics of Ciprofloxacin in Humans. Antimicrobial Agents and Chemotherapy, 2004, 48, 3850-3857.	3.2	54
241	Positron emission tomography imaging of adrenal masses: 18F-fluorodeoxyglucose and the 11?-hydroxylase tracer 11C-metomidate. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1224-30.	6.4	93
242	Labelling of EDTMP (Multibone®) with [111In], [99mTc] and [188Re] using different carriers for "cross complexation― Applied Radiation and Isotopes, 2004, 60, 653-658.	1.5	11
243	New aspects on the preparation of [11C]acetate—a simple and fast approach via distillation. Applied Radiation and Isotopes, 2004, 61, 1147-1150.	1.5	19
244	Binding studies of [18F]-fluoride and polyphosphonates radiolabelled with [111In], [99mTc], [153Sm], and [188Re] on bone compartments: a new model for the pre vivo evaluation of bone seekers?. Bone, 2004, 34, 835-844.	2.9	16
245	Biological evaluation of 2′-[18F]fluoroflumazenil ([18F]FFMZ), a potential GABA receptor ligand for PET. Nuclear Medicine and Biology, 2004, 31, 291-295.	0.6	43
246	Bone lesion detection with carrier-added 99mTc-EDTMP in comparison with 99mTc-DPD. Nuclear Medicine Communications, 2004, 25, 361-365.	1.1	17
247	In vivo and in vitro evaluation of [ $18F$ ]FETO with respect to the adrenocortical and GABAergic system in rats. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1398-1401.	6.4	35
248	Brain tumour imaging with PET: a comparison between [ 18 F]fluorodopa and [ 11 C]methionine. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1561-1567.	6.4	259
249	Synthesis of [18F]FETO, a novel potential 11-? hydroxylase inhibitor. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 379-388.	1.0	22
250	A general method for the fluorine-18 labelling of fluoroquinolone antibiotics. Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 715-727.	1.0	10
251	Radiosynthesis of 3-(2′-[18F]fluoro)-flumazenil ([18F]FFMZ). Journal of Labelled Compounds and Radiopharmaceuticals, 2003, 46, 1229-1240.	1.0	12
252	The labelling of Nanocoll® with [111In] for dual-isotope scanning. Applied Radiation and Isotopes, 2003, 59, 337-342.	1.5	9

#	Article	IF	CITATIONS
253	Comparison of three different purification methods for the routine preparation of [11C] Metomidate. Applied Radiation and Isotopes, 2003, 59, 125-128.	1.5	8
254	Synthesis of fluorine-18-labeled ciprofloxacin for PET studies in humans. Nuclear Medicine and Biology, 2003, 30, 285-291.	0.6	123
255	Synthesis of [68Ga]Gallium Dota-(Tyr3)-Octreotide Acetate ([68Ga]-Dotatoc)., 0,, 321-334.		3
256	Synthesis of 2-(4-N-[11C]Methylaminophenyl)-6-Hydroxybenzothiazole ([11C]6-OH-BTA-1; [11C]PIB). , 0, , 177-189.		0
257	Synthesis of 3-Amino-4-[2-(N-Methyl-N-[11C]Methyl-Amino-Methyl)Phenylsulfanyl]-Benzonitrile ([11C]DASB)., 0,, 285-296.		0